Clinical Trials Browser

INDUSTRY × Bronchiolitis Obliterans Syndrome × 1 year × Clear all

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease, Polycythemia Vera, Thalassemia, Leukemia, Myeloid, Acute, Primary Myelofibrosis

NCT04710576 2026-03-16

AGAVE-201

Phase 2 Active not recruiting

241 enrolled 11 charts 1 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

NCT01804686 2026-03-12

CAN3001

Phase 3 Recruiting

700 enrolled

LymphoidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT04063215 2026-01-15

A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy

Phase 1/2 Completed

24 enrolled 67 charts

Lymphoid

Brain Injuries, Traumatic, Bronchiolitis Obliterans Syndrome, Cerebral Palsy, Lymphoma, Follicular, Trauma, Nervous System, Intracranial Hemorrhages, Stroke, Hypoxia-Ischemia, Brain

NCT03774082 2025-12-11

REACH 5

Phase 2 Completed

46 enrolled 21 charts

Lymphoid

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease, Lymphoma, Follicular

NCT03790332 2025-10-21

Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)

Phase 1/2 Completed

59 enrolled 1 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

NCT06427811 2025-10-16

ASC4INDIA

Phase 4 Active not recruiting

85 enrolled

MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05951777 2025-09-29

Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury

Phase 2 Recruiting

51 enrolled

Lymphoid

Brain Injuries, Traumatic, Bronchiolitis Obliterans Syndrome, Lymphoma, Follicular, Trauma, Nervous System, Intracranial Hemorrhages

NCT04795427 2025-04-18

Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors

Phase 2 Completed

84 enrolled

MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT06462365 2025-04-15

Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)

Phase 1 Recruiting

36 enrolled

LymphoidMyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Clinical Trials

CINC424A2X01B Rollover Protocol

AGAVE-201

CAN3001

A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy

REACH 5

Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)

ASC4INDIA

Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury

Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors

Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)